Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan
Cancer Treatment Reviews · 2024-04 · 125 · 102720
DOI: 10.1016/j.ctrv.2024.102720 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2024-04. Verfasst von Rebecca S Heist und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Harvard University, Boston, MA, USA. Electronic address…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms, Lung Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 82-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Harvard University, Boston, MA, USA. Electronic address: rheist@partners.org.
- Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
- Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA, USA.
- Department of Pulmonary Medicine and Medical Oncology, Wakayama Medical University Hospital, Wakayama Medical University Graduate School of Medicine, Wakayama, Japan.
- Yale Cancer Center, New Haven, CT, USA.
- Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
Zitieren
APA
Heist, R. S., Sands, J., Bardia, A., Shimizu, T., Lisberg, A., Krop, I., Yamamoto, N., Kogawa, T., Al-Hashimi, S., Fung, S. S. M., Galor, A., Pisetzky, F., Basak, P., Lau, C., & Meric-Bernstam, F. (2024). Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treatment Reviews, 125, 102720. https://doi.org/10.1016/j.ctrv.2024.102720
Vancouver
Heist RS, Sands J, Bardia A, Shimizu T, Lisberg A, Krop I, et al. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treatment Reviews. 2024;125:102720. doi:10.1016/j.ctrv.2024.102720
BibTeX
@article{Heist2024,
author = {Heist, Rebecca S and Sands, Jacob and Bardia, Aditya and Shimizu, Toshio and Lisberg, Aaron and Krop, Ian and Yamamoto, Noboru and Kogawa, Takahiro and Al-Hashimi, Saba and Fung, Simon S M and Galor, Anat and Pisetzky, Francesca and Basak, Priyanka and Lau, Cindy and Meric-Bernstam, Funda},
title = {Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan},
journal = {Cancer Treatment Reviews},
year = {2024},
volume = {125},
pages = {102720},
doi = {10.1016/j.ctrv.2024.102720}
}
EUVIMED